Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06276764Enrolling By Invitation

The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)

Role: lead

NCT06157671Enrolling By Invitation

The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma

Role: lead

NCT06276803Not Yet Recruiting

The LINFU® U.S. Registry for the in the General Population Without Risk Factors

Role: lead

NCT06276738Not Yet Recruiting

The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease

Role: lead

NCT04793633Enrolling By Invitation

Evaluating LINFU™: A Noninvasive Method for Collecting Pancreatic Cells for the Early Detection of Pancreatic Cancer

Role: lead

NCT05161013Not ApplicableCompleted

A Proof-of-Concept Study Evaluating LINFU™

Role: lead

All 6 trials loaded